Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Wall Street Zen

Key Points

• Unicycive Therapeutics (NASDAQ: UNC) has been upgraded from a "sell" to a "hold" rating by investment analysts at Wall Street Zen.
• HC Wainwright has issued a "strong-buy" rating for Unicycive Therapeutics, setting a target price of $90.00, while the stock has a consensus target price of $60.00.
• The company's last earnings report indicated an EPS of ($0.52), which surpassed analysts' expectations of ($0.70).

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Separately, HC Wainwright upgraded shares of Unicycive Therapeutics to a "strong-buy" rating and set a $90.00 price target on the stock in a research report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $60.00.

Unicycive Therapeutics Stock Down 1.9%

NASDAQ UNCY traded down $0.08 on Friday, hitting $4.21. The stock had a trading volume of 32,087 shares, compared to its average volume of 370,601. Unicycive Therapeutics has a one year low of $3.24 and a one year high of $11.00. The stock has a market cap of $74.35 million, a price-to-earnings ratio of -1.02 and a beta of 1.87. The company's 50-day moving average is $4.55 and its two-hundred day moving average is $5.55.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.18. On average, sell-side analysts anticipate that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics in the second quarter valued at $55,000. JPMorgan Chase & Co. increased its position in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after acquiring an additional 21,525 shares during the period. Northern Trust Corp increased its position in Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after acquiring an additional 34,183 shares during the period. Geode Capital Management LLC increased its position in Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after acquiring an additional 122,089 shares during the period. Finally, Vivo Capital LLC grew its stake in Unicycive Therapeutics by 14.0% during the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company's stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.